Global Pharma Price Wars Could Drive Up Drug Costs in Israel
Pharmaceutical companies facing US price pressures are seeking higher drug prices in Europe, potentially impacting Israel. A Coface report highlights significant price differences between the US and Europe, with European nations adopting varied strategies to manage costs. Israel's current moderated drug prices are linked to European pricing and HMO bargaining power, but future increases are possible. This situation follows recent price hikes for eggs in Israel and ongoing general price increases for essential goods.
הידיעה ב-7 שורות · תקציר של baba
- US pressure on drug prices is causing pharma companies to seek higher prices in Europe.
- Patented drugs in the US are four times more expensive than in Europe, according to Coface.
- European countries like the UK, Germany, and France are implementing different strategies to control drug costs.
- Major pharma companies are shifting billions in investment from Europe to the US.
- China is increasing its share of global clinical trials, surpassing Europe.
- Israel's drug prices may rise due to European pricing changes and dependence.
- Israeli consumers recently saw price hikes for eggs and other essential goods.
US pressure to lower drug prices, particularly for Medicare and Medicaid, is impacting pharmaceutical company profits. To compensate, these companies are seeking price increases from European governments, indirectly supported by the US argument that other nations should share research and development costs. A Coface report indicates that patented drugs in the US are, on average, four times more expensive than in Europe. The US leads OECD countries in prescription drug spending as a percentage of GDP.
This price disparity in the US is attributed to a fragmented market dominated by Pharmacy Benefit Managers (PBMs) that inflate prices. European nations are responding differently to these pressures due to the lack of a unified EU pricing mechanism. The UK has agreed to a 25% increase in net prices for new drugs and a doubling of public spending by 2036 to maintain its innovation hub status and secure US tariff exemptions. Germany has taken a firm stance, increasing mandatory manufacturer rebates to the state from 7% to 15.5%, saving €4.1 billion but raising patient co-pays by over 50% and risking that companies may withhold new drug launches.
France is navigating a middle path, allowing high launch prices for breakthrough drugs but implementing sharp subsequent cuts to save €3 billion while incentivizing local R&D. Europe's capacity to absorb price hikes is constrained by significant deficits and an aging population, with projections indicating that by 2045, over 30% of the populations in Italy, Spain, and Germany will be aged 65 and above. Major pharmaceutical companies like AstraZeneca, Johnson & Johnson, and Roche are redirecting tens of billions of dollars in investments to the US. Meanwhile, China is surpassing Europe in global clinical trials, with its share increasing from 11% to 17% between 2019 and 2025.
In Israel, the local market currently benefits from moderated prices due to the pegging of maximum prices to Europe and the bargaining power of health maintenance organizations (HMOs), according to Michael Nachmanovitch, CEO of Coface Israel. However, this dependence means that any shift in pricing trends in Europe could lead to increased costs in Israel. The long-term challenge will be balancing price moderation with maintaining the market's attractiveness for the launch of new drugs. This comes as Israeli consumers recently faced price increases for eggs, adding to a general trend of rising prices for essential goods, despite a recent drop in fuel prices which may not be permanent.
מוזכרים
לא אותו אירוע: ידיעות אחרות שחולקות עם הידיעה הזו אנשים, מקומות או נושא. רקע, תגובות והמשכים.
